The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas.
 
Weijie Ma
No Relationships to Disclose
 
Shuai Chen
No Relationships to Disclose
 
Nancy L. Ogihara
No Relationships to Disclose
 
Jasmine Huynh
No Relationships to Disclose
 
Ariel Yen
No Relationships to Disclose
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sanko; Debiopharm Group; Eisai; EMD Serono; Genentech; Genmab; Janssen; Lilly; Novartis; Regeneron; Sanofi; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Meyers Squibb (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - EMD Serono; Lilly; Novartis; Takeda
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
James A. Radosevich
Employment - LabyRx Immunological Therapeutics
Stock and Other Ownership Interests - LabyRx Immunological Therapeutics
Research Funding - LabyRx Immunological Therapeutics
Patents, Royalties, Other Intellectual Property - LabyRx Immunological Therapeutics
 
Michael Babich
Employment - LabyRx Immunological Therapeutics
Stock and Other Ownership Interests - LabyRx Immunological Therapeutics
Research Funding - LabyRx Immunological Therapeutics
Patents, Royalties, Other Intellectual Property - LabyRx Immunological Therapeutics
 
Tianhong Li
Honoraria - Tempus
Research Funding - AstraZeneca (Inst); Hengrui Therapeutics (Inst); LabyRx Immunological Therapeutics (Inst); Merck (Inst); Nvigen (Inst); OncoImmune/OncoC4 (Inst); Pfizer (Inst); RasCal (Inst); Tempus (Inst)